Electronic Arts (ERTS, $15.50, up $0.64) posted weaker-than-expected earnings after the bell and said it would delay the release of several hit games. And guess what? The stock went up. The company reported a profit of $0.56 a share versus expectations of $0.88 a share for the fourth quarter butRead more
EA Misses, Cuts Jobs
Visa Call Option Activity/ EA Update
Biotech Grumblings
Genentech (DNA, $82.10, up $0.86) came out with some great news yesterday after the bell and said a late-stage study combining Avastin with Tarceva to treat lung cancer was a huge success. Tarceva is a drug from OSI Pharmaceutical’s (OSIP, $36.39, up $0.79) pipeline and is marketed by Genentech. TheRead more
Electronic Arts On Deck
Google Earth Creating Buzz
Update on GLD, ERTS
Weekly Wrap for 2/1/09
1. Commentary 2. Month-end Review 3. Opening and Managing a Trading Account 4. Using Option Straddles 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market suffered its fourth straight losing week but the losses were kept to less than 1%. The Dow got off to aRead more
Roche Goes Hostile
Roche threw us a curveball this morning and took its bid for Genentech (DNA, $80.95, down $3.14) directly to the shareholders. The company is now offering about $42 billion, or $86.50 a share for Genentech which is $2.50 less than the offer it made last July. Hogwash. Roche’s attempt toRead more